FHTX logo

Foghorn Therapeutics Inc



+ $3.45 (92.00%) This month

Closed: 27 Feb 2024 21:00 US/Eastern

Key details






null, null




Pharmaceutical Preparation Manufacturing

About Foghorn Therapeutics Inc

foghorn therapeutics inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. the company uses its proprietary gene traffic control platform to identify, validate, and potentially drug targets within the system. it is developing fhd-286, a small-molecule enzymatic inhibitor of brg1 and brm for the treatment of acute myeloid leukemia and uveal melanoma; and fhd-609, a small molecule protein degrader of brd9 to treat patients with synovial sarcoma. the company is also developing preclinical and discovery programs, including selective brm targeting non-small-cell lung cancer; and selective arid1b modulators for bladder, ovarian, and endometrial cancer. it has a collaboration with merck sharp & dohme corp. to discover and develop novel oncology therapeutics against a transcription factor target. the company was founded in 2015 and is headquartered in cambridge, massachusetts.

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday pricing and company data provided by IEX.
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG